Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Thiazide Diuretics Market size was valued at USD 111.7 million in 2024 and is set to exceed USD 282.56 million by 2037, expanding at over 7.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of thiazide diuretics is estimated at USD 118.73 million.
The increasing prevalence of hypertension drives the demand for thiazide diuretics. These medications effectively reduce blood pressure by eliminating excess fluid and sodium, making them a primary choice in managing hypertension and its associated risks. With a systolic blood pressure of more than 130 mmHg or a diastolic blood pressure of more than 80 mmHg, or with hypertension medication, over half of adults (48.1%, 119.9 million) have hypertension. Approximately 1 in 4 persons with hypertension (22.5 percent, 27.0 million) have their hypertension under control.
Further, the predicted prevalence of hypertension at the CCG level varies from 16% to 33.8%. Hypertension in general practitioner practices falls between 18.8% to 31%, with the top and worst 10% of practices excluded.
Thiazide Diuretics Sector: Growth Drivers and Challenges
Growth Drivers
- Emerging Economies- Market expansion in developing nations with a focus on accessible healthcare boosts demand for cost-effective medications like thiazide diuretics, fostering thiazide diuretics market growth.
- Awareness Programs- Increased awareness about hypertension management fosters demand for thiazide diuretics among patients and healthcare providers, driving market growth
- Rise in precision Medication- Precision medicine is a relatively new area of medicine that bases therapy recommendations on a patient's lifestyle, genetic composition, and environment. The success in treating and preventing chronic diseases has led to a rise in the popularity of precision medicine. This makes it possible for medical professionals and academics to forecast illness prevention and treatment more accurately. Personalized or individualized medicine are other terms for precision medicine. Treatment of epigenetics mutation within healthy cells is its main goal. Compared to conventional medications, precision medicine has a lower risk of side effects and can be utilized for tailored treatment.
- Government Initiatives – Healthcare policies favoring cost- effective treatments promote thiazide diuretics use, influencing thiazide diuretics market growth due to their affordability.
Challenges
- Changing Treatment Guidelines- Evolving clinical guidelines and recommendations for hypertension management might influence the choice of medications. If thiazide diuretics are no longer prioritized as first-line treatments, their thiazide diuretics market demand could decrease.
- Limited Efficacy in certain Patient Groups.
- Competition from other classes of antihypertensive drugs.
Thiazide Diuretics Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.4% |
|
Base Year Market Size (2024) |
USD 111.7 million |
|
Forecast Year Market Size (2037) |
USD 282.56 million |
|
Regional Scope |
|
Thiazide Diuretics Segmentation
Application (Hypertension, Cardiovascular Disorder, Hepatic Disorders, Kidney Disorders)
The hypertension segment is estimated to account for 48% of the global thiazide diuretics market during the forecast period. The rise in the number of hypertension drugs delivered through retail pharmacies and the rise in the number of retail pharmacies in highly developed countries, create opportunities. Further, the sedentary lifestyle adopted by the population, has resulted in cardiovascular diseases, providing opportunities for the segment’s growth.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
The retail pharmacies segment in the thiazide diuretics market is expected to hold a major revenue share. The retail pharmacies segment has undergone a technological revolution that has fuelled expansion and improved client satisfaction. Prescription filling procedures are made easier by pharmacy automation systems, clients can get prescriptions online, and telemedicine services enable remote medication delivery and consultation. In addition to increasing the effectiveness of retail pharmacies, these technological advancements draw in more clients, which helps the industry grow.
Our in-depth analysis of the global market includes the following segments:
|
Application |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportThiazide Diuretics Industry - Regional Synopsis
North American Market Forecast
North America industry is likely to account for largest revenue share of 45% by 2037. The market has seen consistent growth due to the prevalent cases of hypertension and related cardiovascular diseases. Thiazide diuretics, such as hydrochlorothiazide (HCTZ) and chlorthalidone, have been among the primary choices for managing hypertension in the region. Factors contributing to this market growth include a high incidence of hypertension among the population, lifestyle-related health issues, and an aging demographic.
APAC Market Statistics
The Asia Pacific region represents a significant and growing market for thiazide diuretics. With a rising prevalence of hypertension and related cardiovascular diseases across countries like China, India, Japan, and others, the demand for effective antihypertensive medications like thiazide diuretics is steadily increasing. Factors such as lifestyle changes, urbanization, and an aging population contribute to this growth.
Companies Dominating the Thiazide Diuretics Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- Sanofi
- Bayer AG
- Centaur Pharmaceuticals Private Limited
- Validus Pharmaceuticals LLC
- Teva Pharmaceutical Industries Ltd.
- Novartis Pharmaceuticals Corporation
- Boehringer Ingelheim International GmbH
- Cipla Inc.
- scPharmaceuticals, Inc.
In the News
- December,2021- Arena Pharmaceuticals, Inc. and Pfizer Inc. announced that they had reached a final agreement whereby Pfizer will purchase Arena, a clinical stage business creating novel therapeutic treatments for the management of several immuno-inflammatory illnesses. Pfizer will purchase all of Arena's outstanding shares under the terms of the agreement for $100 per share in an all-cash deal, for a total equity value of roughly $6.7 billion. Both firms' boards of directors have overwhelmingly approved the deal.
- May,2019- In order to promote clinical research in pulmonary hypertension (PH), with an emphasis on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), Bayer U.S. announced the creation of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards. Over the course of a two-year cycle, the initiative will provide grants totaling up to $1 million.
Author Credits: Radhika Pawar
- Report ID: 3318
- Published Date: Jan 03, 2025
- Report Format: PDF, PPT
